Fungal Infections Therapeutics
1. Brexafemme patent expiration
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc); Reduction in the incidence of recurrent vulvovaginal candidiasis (rvvc) in adult and post-menarchal pediatr...
BREXAFEMME's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8188085 | GLAXOSMITHKLINE | Antifungal agents |
Aug, 2030
(4 years from now) | |
| US10927142 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| US10174074 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | GLAXOSMITHKLINE | Salts and polymorphs of SCY-078 |
Jan, 2035
(9 years from now) | |
| US11534433 | GLAXOSMITHKLINE | Antifungal agents with enhanced activity in acidic pH |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-903) | Nov 30, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 01, 2031 |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
NCE-1 date: 01 June, 2030
Market Authorisation Date: 01 June, 2021
Dosage: TABLET
More Information on Dosage
BREXAFEMME family patents
2. Cancidas patent expiration
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(10 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(10 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Dosage: POWDER
How can I launch a generic of CANCIDAS before it's drug patent expiration?
More Information on Dosage
CANCIDAS family patents
3. Cresemba patent
expiration
Treatment: NA
CRESEMBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459561 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2020
(5 years ago) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(2 months ago) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(1 year, 8 months from now) | |
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(1 year, 8 months from now) | |
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Apr, 2026
(3 months from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(2 years from now) | |
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 06 March, 2015
Dosage: POWDER; CAPSULE
More Information on Dosage
CRESEMBA family patents
4. Eraxis patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON HOLDINGS | Cyclic peptide antifungal agents |
Feb, 2020
(5 years ago) | |
| US7709444 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| US6960564 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Dosage: POWDER
More Information on Dosage
ERAXIS family patents
5. Ertaczo patent expiration
Treatment: Product is approved for the topical treatment of tinea pedis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5135943 | LACER PHARMA | 1H-imidazole derivative compounds and pharmaceutical compositions containing the same |
May, 2014
(11 years ago) | |
Drugs and Companies using SERTACONAZOLE NITRATE ingredient
Market Authorisation Date: 10 December, 2003
Dosage: CREAM
More Information on Dosage
ERTACZO family patents
6. Jublia patent expiration
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toe...
JUBLIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(a month from now) | |
| US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US10478601 | BAUSCH | Applicator |
Apr, 2035
(9 years from now) | |
| US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(8 years from now) | |
| US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(8 years from now) | |
| US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| US8039494 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(8 years from now) | |
| US9861698 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US8486978 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10105444 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jul, 2030
(4 years from now) | |
| US9302009 | BAUSCH | Compositions and methods for treating diseases of the nail |
Oct, 2030
(4 years from now) | |
| US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Dosage: SOLUTION
How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage
JUBLIA family patents
7. Kerydin patent expiration
Treatment: Treatment for onychomycosis that is tinea unguium; Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail
KERYDIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(1 year, 4 months from now) | |
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(a month from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(7 months from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Dosage: SOLUTION
How can I launch a generic of KERYDIN before it's drug patent expiration?
More Information on Dosage
KERYDIN family patents
8. Luzu patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(7 years from now) | |
| US5900488 | BAUSCH | Method for treating mycosis using imidazolylacetonitrile derivatives |
Jan, 2020
(5 years ago) | |
| US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(7 years from now) | |
| US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
| New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Dosage: CREAM
More Information on Dosage
LUZU family patents
9. Mycamine patent expiration
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(10 years ago) | |
| US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(6 years ago) | |
|
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(4 years ago) | |
| US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-821) | Dec 20, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2023 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Dosage: INJECTABLE
How can I launch a generic of MYCAMINE before it's drug patent expiration?
More Information on Dosage
MYCAMINE family patents
10. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(3 years ago) | |
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Dosage: SUSPENSION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
11. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(5 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(5 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Dosage: SOLUTION; TABLET, DELAYED RELEASE
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
12. Rezzayo patent expiration
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10702573 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US9526835 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US8722619 | MUNDIPHARMA | Antifungal agents and uses thereof |
Mar, 2032
(6 years from now) | |
| US11197909 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| US11654196 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2032
(6 years from now) | |
| US11819533 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
13. Vfend patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5567817 | PF PRISM CV | Triazole antifungal agents |
May, 2016
(9 years ago) | |
| US6632803 | PF PRISM CV | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
Drugs and Companies using VORICONAZOLE ingredient
Market Authorisation Date: 24 May, 2002
Dosage: TABLET; POWDER; FOR SUSPENSION
How can I launch a generic of VFEND before it's drug patent expiration?
More Information on Dosage
VFEND family patents
14. Vivjoa patent expiration
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(7 years from now) | |
| US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents